Guangzhou-Israel Biotechnology Fund
Promoting life sciences technologies in China through cross-border investments and international collaborations.
With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.
VIEW ALL
(6 June, 2025) Guangzhou Corebone Medical Technology Co., Ltd., a portfolio company of GIBF, announced that its dental bone powder product has officially obtained the Class III Medical Device Registration Certificate issued by the National Medical Products Administration (NMPA).
(31 March, 2025) BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today, that the company was granted important patent claims in China for its BV100 technology.
（25 February, 2025) Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks.